🧪 Emcure Pharma Slips Despite Clean USFDA Report

ended the December 24, 2025 session down by around 1%, even as the company announced a key regulatory update. The pharma major received the Establishment Inspection Report (EIR) from the US Food and Drug Administration for its manufacturing facility at Lakhtar, Gujarat. Importantly, the USFDA classified the inspection outcome as “No Action Indicated” (NAI), which is considered the best possible regulatory status. Despite this positive development, the stock saw profit booking, suggesting that the news may have already been priced in or broader market sentiment weighed on pharma stocks during the session.